Crystal Genomics(15,650 +4.33%)Announced on the 24th that it has confirmed a’complete response’ in which the tumor completely disappears in the US clinical phase 1 of acute myeloid leukemia (AML) patients of’CG-806′, which was exported in 2016.
According to the annual report of the US partner Aptoz Bioscience, complete remission was found in patients who took 450mg of CG-806 twice a day (BID). There were no side effects even in patients who took multiple doses.
In December of last year, the American Society of Hematology and Cancer (ASH) announced that anti-leukemia activity was observed in one’FLT3′ positive patient (AML) who received repeated chemotherapy. Currently, 30 hospitals in the United States are enrolling patients with acute myelogenous leukemia. The company plans to increase the dose to the next step, 600mg, as complete remission appears at the 450mg level and no toxicity trend is observed.
CG-806 is more than a new drug that inhibits’FLT3 BTK’ developed by Crystal Genomics. In August of last year, Stonelake Capital of the United States compared the preclinical results of CG-806 with AbbVie’s ibrutinib and Merck’ARQ-531′ and analyzed that CG-806 is more likely as a treatment for blood cancer.
The overall results of phase 1 clinical trials will be announced at the European Hematology Association (EHA) in June.
Reporter Minsoo Han [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution